Biykem Bozkurt
Auto-generated profile, based on publicly available information

Biykem Bozkurt

Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, Houston, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2021 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
WMWRITING COMMITTEE MEMBERS
WRITING COMMITTEE MEMBERS
BBBiykem Bozkurt
Biykem Bozkurt
ACAndrew Coats
Andrew Coats
HTHiroyuki Tsutsui
Hiroyuki Tsutsui

1 April 2021 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
BBBiykem Bozkurt
Biykem Bozkurt
ACAndrew Js Coats
Andrew Js Coats
HTHiroyuki Tsutsui
Hiroyuki Tsutsui
MAMagdy Abdelhamid
Magdy Abdelhamid
SAStamatis Adamopoulos
Stamatis Adamopoulos
SZShelley Zieroth
Shelley Zieroth

10 August 2021 in Circulation
Verified
Journal Article
Closed access
BBBiykem Bozkurt
Biykem Bozkurt
IKIshan Kamat
Ishan Kamat
PHPeter Hotez
Peter Hotez
Myocarditis has been recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccinations, especially in young adult and adolescent males. According to the US Centers for Disease Control and Prevention, myocarditis/pericarditis rates are ≈12.6 cases per million doses of second-dose mRNA vaccine among individuals 12 to 39 years of age. In reported cases, patients with myocarditis invariably presented with chest pain, usually 2 to 3 days after a second dose of mRNA vaccination, and had elevated cardiac troponin levels. ECG was abnormal with ST elevations in most, and cardiac MRI was suggestive of myocarditis in all tested patients. There was no evidence of acute COVID-19 or other viral infections. In 1 case, a cardiomyopathy gene panel was negative, but autoantibody levels against certain self-antigens and frequency of natural killer cells were increased. Although the mechanisms for development of myocarditis are not clear, molecular mimicry between the spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and self-antigens, trigger of preexisting dysregulated immune pathways in certain individuals, immune response to mRNA, and activation of immunologic pathways, and dysregulated cytokine expression have been proposed. The reasons for male predominance in myocarditis cases are unknown, but possible explanations relate to sex hormone differences in immune response and myocarditis, and also underdiagnosis of cardiac disease in women. Almost all patients had resolution of symptoms and signs and improvement in diagnostic markers and imaging with or without treatment. Despite rare cases of myocarditis, the benefit-risk assessment for COVID-19 vaccination shows a favorable balance for all age and sex groups; therefore, COVID-19 vaccination is recommended for everyone ≥12 years of age.

26 September 2023 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
BBBiykem Bozkurt
Biykem Bozkurt
TATariq Ahmad
Tariq Ahmad
KAKevin M. Alexander
Kevin M. Alexander
WBWilliam L. Baker
William L. Baker
KBKelly Bosak
Kelly Bosak
BZBoback Ziaeian
Boback Ziaeian

1 March 2021 in JACC
Verified
Journal Article
Closed access
BBBiykem Bozkurt
Biykem Bozkurt
GFGregg C. Fonarow
Gregg C. Fonarow
LGLee R. Goldberg
Lee R. Goldberg
MGMaya Guglin
Maya Guglin
RJRichard A. Josephson
Richard A. Josephson
EWEugene Wolfel
Eugene Wolfel

7 September 2022 in JACC: Heart Failure
Verified
Journal Article
Open access
GSGianluigi Savarese
Gianluigi Savarese
TKTakuya Kishi
Takuya Kishi
OVOrly Vardeny
Orly Vardeny
SESamuel Adamsson Eryd
Samuel Adamsson Eryd
JBJohan Bodegård
Johan Bodegård
BBBiykem Bozkurt
Biykem Bozkurt
Guidelines recommend early initiation of multiple guideline-directed medical therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart failure and reduced ejection fraction. Understanding GDMT use is critical to improving clinical practice. This study sought to describe GDMT use in Japan, Sweden, and the United States in contemporary real-world settings. EVOLUTION HF (Utilization of Dapagliflozin and Other Guideline Directed Medical Therapies in Heart Failure Patients: A Multinational Observational Study Based on Secondary Data) is an observational cohort study using routine-care databases. Patients initiating any GDMT within 12 months of a hospitalization for heart failure (hHF) discharge were included. Dapagliflozin (the only sodium-glucose cotransporter-2 inhibitor approved at study onset), sacubitril/valsartan, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) were considered separately. Doses and discontinuation were assessed in the 12 months following initiation. Target dose was defined as ≥100% of the guideline-recommended dose. Overall, 266,589 patients were included. Mean times from hHF to GDMT initiation were longer for novel GDMTs (dapagliflozin or sacubitril/valsartan) than for other GDMTs: 39 and 44 vs 12 to 13 days (Japan), 44 and 33 vs 22 to 31 days (Sweden), and 33 and 19 vs 18 to 24 days (United States). Pooled across countries, proportions of patients who discontinued therapy (not including switches from ACE inhibitor or ARB to sacubitril/valsartan) within 12 months were 23.5% (dapagliflozin), 26.4% (sacubitril/valsartan), 38.4% (ACE inhibitors), 33.4% (ARBs), 25.2% (beta-blockers), and 42.2% (MRAs). Corresponding target dose achievements were 75.7%, 28.2%, 20.1%, 6.7%, 7.2%, and 5.1%, respectively. Initiation of novel GDMTs is delayed compared with other GDMTs. Few patients received target doses of GDMTs requiring uptitration. Persistence was higher for dapagliflozin than other GDMTs.